Title: Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
138530-95-7
151602-49-2
161796-78-7
103577-40-8
103577-45-3
73590-58-6
1956319-38-2 | 2-(Chloromethyl)-6-methylpyrazine hydrochloride | AA01EDRR | MFCD22576123
40636-99-5 | 4-Chloro-5-hydroxyfuran-2(5H)-one | AA01EMYQ | MFCD01218563
1805578-52-2 | 2-Bromo-5-fluoro-4-nitropyridine | AA01FOSA | MFCD28740491
910410-89-8 | 2-(3-fluoropyridin-4-yl)ethan-1-amine | AA01FQBF | MFCD08449627
753922-08-6 | 6-Benzyloxy-3-methyl-indazole-1-carboxylic acid tert-butyl ester | AA01FQX1
2227035-28-9 | 4-Chloro-2,6-diiodo-3-methyl-phenol | AA01FR0M
1839552-43-0 | Chlorohydro[2-[[[3-[methyl[3-(4-morpholinyl-κN4)propyl]amino-κN]propyl]thio-κS]methyl]phenyl-κC]iridium(III) | AA01FR3Q
1884137-92-1 | Dimethylphenylphosphine(1,5-cyclooctadiene)[1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene] iridium(I) tetrakis(3,5-bis(trifluoromethyl)phenylborate | AA01FR4V
629625-30-5 | 2-(Bromomethyl)-4-methoxy-3,5-dimethylpyridine hydrobromide | AA01FRYS | MFCD31698473
1092564-34-5 | Morpholin-4-yl-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-trifluoromethyl-phenyl]-methanone | AA01FSF3 | MFCD28718144
899806-45-2
171661-55-5
159064-78-5
2034357-46-3
877656-00-3
1980781-22-3